Marcos Palatnik Selected Research

N-Glycosyl Hydrolases

1/2017	Leishmania donovani Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human Visceral Leishmaniasis.
1/2017	A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the Leishmania donovani Nucleoside Hydrolase (NH36) Optimizes Cross-Protection against Leishmania amazonesis Infection.
1/2014	Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marcos Palatnik Research Topics

Disease

9	Visceral Leishmaniasis (Kala Azar) 01/2017 - 11/2002
6	Infections 01/2017 - 06/2003
3	Leishmaniasis 01/2017 - 11/2010
3	Hypersensitivity (Allergy) 01/2005 - 11/2002
2	Cutaneous Leishmaniasis 01/2017 - 01/2014
1	Ganglion Cysts (Ganglion) 12/2003

Drug/Important Bio-Agent (IBA)

8	VaccinesIBA 01/2017 - 11/2002
5	AntigensIBA 01/2017 - 11/2002
5	Fluorometholone (FML)FDA Link 05/2012 - 11/2002
3	N-Glycosyl HydrolasesIBA 01/2017 - 01/2014
3	SaponinsIBA 05/2012 - 11/2002
2	CytokinesIBA 01/2017 - 12/2003
2	Combined VaccinesIBA 01/2014 - 11/2010
2	fucose-binding lectinIBA 06/2004 - 12/2003
2	Immunoglobulin G (IgG)IBA 06/2003 - 11/2002
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2017
1	EpitopesIBA 01/2017
1	BradykininIBA 11/2012
1	Bradykinin B2 ReceptorIBA 11/2012
1	GTP-Binding Proteins (G-Protein)IBA 11/2012
1	Coloring Agents (Dyes)IBA 09/2004
1	saponin QA-21V1 (QS21)IBA 11/2002
1	Immunoglobulin M (IgM)IBA 11/2002
1	Interleukin-12 (IL 12)IBA 11/2002

Therapy/Procedure

3	Immunotherapy 01/2014 - 12/2003
1	Therapeutics 12/2003